SARS-CoV-2 vaccination and thrombotic risk in myeloproliferative neoplasms

Letter Oncology

Second versus first wave of COVID-19 in patients with MPN

Tiziano Barbui et al.

LEUKEMIA (2022)

Article Hematology

Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies

Akio Mori et al.

Summary: This study investigates the response to COVID-19 vaccination in patients with myeloid malignancies. The findings suggest that most patients with myeloid malignancies develop an immune response to the vaccine, but leukemia patients may have lower antibody levels. This indicates that the response to the vaccine may be related to disease subtype and treatment status.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Article Hematology

Risk of venous thromboembolism after COVID-19 vaccination

Damon E. Houghton et al.

Summary: This study analyzed the incidence of VTE before and after COVID-19 vaccination. The results showed that there was no increased risk of acute VTE post-vaccination for the authorized vaccines in the United States.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)

添加到收藏夹

Article Hematology

Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations

Monia Marchetti et al.

Lancet Haematology (2022)

添加到收藏夹

Letter Oncology

Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine

M. Breccia et al.

LEUKEMIA (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Population-wide persistent hemostatic changes after vaccination with ChAdOx1-S

Bas de Laat et al.

Summary: A study found that after receiving the ChAdOx1-S vaccine, the levels of prothrombin and fibrinogen in the blood significantly decreased. Vaccinated individuals had a procoagulant profile in thrombin generation, along with endothelial activation and persistent immune system activity, which could increase the risk of thrombotic events.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)

添加到收藏夹

Article Oncology

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Tiziano Barbui et al.

Summary: The study found a high risk of mortality among MPN patients during COVID-19 infection, especially in MF patients and those discontinuing Ruxo treatment. Further investigation is needed on the role of Ruxo treatment and its interruption in affecting mortality in MPN patients with COVID-19.

LEUKEMIA (2021)

添加到收藏夹

Article Oncology

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

Tiziano Barbui et al.

Summary: A multicenter European retrospective study found that despite receiving LMW-heparin prophylaxis, patients with essential thrombocythemia (ET) still experienced arterial and venous thrombotic events, with ET patients being more susceptible to VTE. Notably, ET patients had significantly lower platelet count at COVID-19 diagnosis, and this was associated with a higher mortality rate for pneumonia. Independent risk factors for thrombosis included transfer to ICU, neutrophil/lymphocyte ratio, and ET phenotype. Further research is needed to tailor new antithrombotic regimens for MPN patients.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Nicola P. Klein et al.

Summary: This study conducted interim analysis of safety surveillance data of mRNA COVID-19 vaccines and found that the incidence of selected serious outcomes within 1-21 days post-vaccination was not significantly higher compared with 22-42 days post-vaccination. Surveillance is ongoing despite wide confidence intervals for many outcomes.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis

Sue Pavord et al.

Summary: Phenotypes of VITT were defined in 220 patients in the United Kingdom who presented a median of 14 days after the first ChAdOx1 nCoV-19 vaccination. Half had cerebral venous sinus thrombosis, a third of whom also had intracranial hemorrhage. Mortality was 22%. Intravenous immune globulin may reverse VITT.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

Noam Barda et al.

Summary: The study found that after receiving the BNT162b2 vaccine, most adverse events were not associated with an increased risk, although there was a slight increase in the risk of myocarditis. On the other hand, infection with the Covid-19 virus significantly increased the risk of many serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Hematology